Singulair, a commonly prescribed medication to treat asthma and allergies, may provide relief for the common cold, according to a study conducted at Allegheny General Hospital.
The hospital presented the study today at the annual meeting of the American Academy of Allergy, Asthma and Immunology in San Diego, according to a press release.
"This study showed that treatment with Singulair (montelukast) resulted in a faster resolution of signs and symptoms of the common cold," said Dr. Deborah Gentile, the study's lead investigator and director of research for the AGH Division of Allergy, Asthma and Immunology.
The study examined 81 participants; 41 received a placebo and 40 received Singulair. Study participants began treatment for their cold within 24 hours of the cold's onset. They were required to continue treatment once a day for five consecutive days and were asked to complete a questionnaire on how they felt on each of those days. In addition, participants were asked that when they blew their nose, to keep the tissues in a bag to be weighed. The weight of the bags was less for patients taking Singulair than for those who weren't.
"We found that the cold symptoms and runny nose, as well as the duration of the cold, were cut in half in the group that took Singulair," Dr. Gentile said.
"Singulair works by blocking the effects of leukotrienes, chemicals that are produced by our body during episodes of inflammation or swelling and are linked to the development of cold symptoms and runny nose. The results of our study suggest that blocking leukotrienes may reduce or prevent these conditions."
The hospital also reported that gamma interferon, a chemical naturally made by the body in response to infection, may be key to predicting which children will be more susceptible to developing an ear infection following a bout with the common cold. The results are also being presented at the San Diego conference.
"Ear infections are the number one reason children visit the doctor," said Dr. David Skoner, lead investigator for that study.
"Because ear infections are frequently triggered by the common cold and occur in only a subset of children, developing a method to identify those patients at 'high risk' of ear infections following a cold would result in a significant advantage in the evaluation and management of the illness."
Dr. Skoner and his colleagues studied 140 children, age 18 months to 3, for three years, following them for the development of an ear infection after a cold. The participants had their ears checked every two weeks, and a DNA sample for gene testing was collected from all children by gently brushing the inside of their mouths with a soft brush.
"We found that children who had a particular type of gene associated with high levels of gamma interferon developed 30 percent fewer ear infections following a cold than those who had lower levels of gamma interferon," Dr. Skoner said.
According to Dr. Skoner, future studies are planned, and if they yield similar results, genetic testing may become a tool for identifying "at risk" children who may benefit from the selective use of preventive or early intervention treatment of ear infections.
More details in tomorrow's Pittsburgh Post-Gazette.




Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.